Biotechnologies Assets SA (BST.MC)

EUR 0.3

(2.54%)

Total Liabilities Summary of Biotechnologies Assets SA

Biotechnologies Assets SA's latest annual total liabilities in 2023 was 10.07 Million EUR , down -30.99% from previous year.
Biotechnologies Assets SA's latest quarterly total liabilities in 2023 FY was 10.07 Million EUR , down -30.99% from previous quarter.
Biotechnologies Assets SA reported annual total liabilities of 14.6 Million EUR in 2022, down -6.02% from previous year.
Biotechnologies Assets SA reported annual total liabilities of 15.53 Million EUR in 2021, down -5.08% from previous year.
Biotechnologies Assets SA reported quarterly total liabilities of 10.07 Million EUR for 2023 Q4, up 0.0% from previous quarter.
Biotechnologies Assets SA reported quarterly total liabilities of 9.56 Million EUR for 2023 Q1, down -34.52% from previous quarter.

Annual Total Liabilities Chart of Biotechnologies Assets SA (2023 - 2010)

Historical Annual Total Liabilities of Biotechnologies Assets SA (2023 - 2010)

Year	Total Liabilities	Total Liabilities Growth
2023	10.07 Million EUR	-30.99%
2022	14.6 Million EUR	-6.02%
2021	15.53 Million EUR	-5.08%
2020	16.36 Million EUR	-80.77%
2019	85.1 Million EUR	46.62%
2018	58.04 Million EUR	507.37%
2017	9.55 Million EUR	19.22%
2016	8.01 Million EUR	10.9%
2015	7.22 Million EUR	3.17%
2014	7 Million EUR	40.0%
2013	5 Million EUR	5.2%
2012	4.75 Million EUR	1.37%
2011	4.69 Million EUR	65.3%
2010	2.83 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2023 Q2	9.56 Million EUR	0.0%
2023 Q4	10.07 Million EUR	0.0%
2023 Q1	9.56 Million EUR	-34.52%
2023 Q3	10.07 Million EUR	5.38%
2023 FY	10.07 Million EUR	-30.99%
2022 FY	14.6 Million EUR	-6.02%
2022 Q2	15.55 Million EUR	0.0%
2022 Q4	14.6 Million EUR	0.0%
2021 Q2	16.65 Million EUR	0.0%
2021 Q4	15.53 Million EUR	0.0%
2021 FY	15.53 Million EUR	-5.08%
2020 FY	16.36 Million EUR	-80.77%
2020 Q2	90.46 Million EUR	0.0%
2020 Q4	16.36 Million EUR	0.0%
2019 FY	85.1 Million EUR	46.62%
2019 Q4	85.1 Million EUR	0.0%
2019 Q2	66.13 Million EUR	0.0%
2018 FY	58.04 Million EUR	507.37%
2018 Q4	58.04 Million EUR	0.0%
2018 Q2	53.4 Million EUR	0.0%
2017 Q4	9.55 Million EUR	0.0%
2017 FY	9.55 Million EUR	19.22%
2017 Q2	8.34 Million EUR	0.0%
2016 Q2	7.46 Million EUR	0.0%
2016 Q4	8.01 Million EUR	0.0%
2016 FY	8.01 Million EUR	10.9%
2015 Q4	7.22 Million EUR	0.0%
2015 FY	7.22 Million EUR	3.17%
2015 Q2	6.84 Million EUR	0.0%
2014 Q4	7 Million EUR	0.0%
2014 Q2	6.79 Million EUR	0.0%
2014 FY	7 Million EUR	40.0%
2013 Q4	5 Million EUR	0.0%
2013 FY	5 Million EUR	5.2%
2013 Q2	5.12 Million EUR	0.0%
2012 Q2	4.76 Million EUR	0.0%
2012 FY	4.75 Million EUR	1.37%
2012 Q4	4.75 Million EUR	0.0%
2011 Q4	4.69 Million EUR	0.0%
2011 Q2	4.04 Million EUR	0.0%
2011 FY	4.69 Million EUR	65.3%
2010 FY	2.83 Million EUR	0.0%
2010 Q4	2.83 Million EUR	0.0%

Peer Total Liabilities Comparison of Biotechnologies Assets SA

Name	Total Liabilities	Total Liabilities Difference
Atrys Health, S.A.	332.45 Million EUR	96.969%
Pharma Mar, S.A.	147.78 Million EUR	93.182%
Laboratorios Farmaceuticos Rovi, S.A.	256.39 Million EUR	96.07%